Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | terminated | Phase 3 | 174 | Abnoba GmbhINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | terminated | Phase 3 | 19 | NRG OncologyOTHER | 3 | May 20, 2026 |
| clinicaltrials |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment(CONTACT-03) | terminated | Phase 3 | 522 | Hoffmann-La RocheINDUSTRY | 15 | Mar 19, 2026 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | terminated | Phase 3 | 62 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03408652 | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies(MOSCAR) | terminated | Phase 3 | 1 | Centre Leon BerardOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | terminated | Phase 3 | 118 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | terminated | Phase 3 | 724 | SFJ Pharma Ltd. IIINDUSTRY | 9 | Sep 20, 2019 | clinicaltrials |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | terminated | Phase 3 | 77 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma(ADAPT) | terminated | Phase 3 | 462 | Argos TherapeuticsINDUSTRY | 8 | Jun 14, 2018 | clinicaltrials |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 3 | 47 | Spectrum Pharmaceuticals, IncINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | terminated | Phase 3 | 521 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 8, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | terminated | Phase 3 | 66 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Dec 13, 2016 | clinicaltrials |
| NCT00974818 | Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients | terminated | Phase 3 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00384891 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | terminated | Phase 3 | 190 | Medical Enterprises Europe B.V.INDUSTRY | 4 | Oct 7, 2014 | clinicaltrials |
| NCT00042887 | Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | terminated | Phase 3 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer | terminated | Phase 3 | 600 | Agenus Inc.INDUSTRY | 2 | Sep 7, 2012 | clinicaltrials |
| NCT00237575 | Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | terminated | Phase 3 | 100 | University of KentuckyOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00311467 | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma | terminated | Phase 3 | 172 | Central European Cooperative Oncology GroupOTHER | 1 | May 16, 2012 | clinicaltrials |
| NCT00003824 | S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer | terminated | Phase 3 | 114 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 9, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials